Cargando…
Does the kappa opioid receptor system contribute to pain aversion?
The kappa opioid receptor (KOR) and the endogenous peptide-ligand dynorphin have received significant attention due the involvement in mediating a variety of behavioral and neurophysiological responses, including opposing the rewarding properties of drugs of abuse including opioids. Accumulating evi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233910/ https://www.ncbi.nlm.nih.gov/pubmed/25452729 http://dx.doi.org/10.3389/fphar.2014.00253 |
_version_ | 1782344771827662848 |
---|---|
author | Cahill, Catherine M. Taylor, Anna M. W. Cook, Christopher Ong, Edmund Morón, Jose A. Evans, Christopher J. |
author_facet | Cahill, Catherine M. Taylor, Anna M. W. Cook, Christopher Ong, Edmund Morón, Jose A. Evans, Christopher J. |
author_sort | Cahill, Catherine M. |
collection | PubMed |
description | The kappa opioid receptor (KOR) and the endogenous peptide-ligand dynorphin have received significant attention due the involvement in mediating a variety of behavioral and neurophysiological responses, including opposing the rewarding properties of drugs of abuse including opioids. Accumulating evidence indicates this system is involved in regulating states of motivation and emotion. Acute activation of the KOR produces an increase in motivational behavior to escape a threat, however, KOR activation associated with chronic stress leads to the expression of symptoms indicative of mood disorders. It is well accepted that KOR can produce analgesia and is engaged in chronic pain states including neuropathic pain. Spinal studies have revealed KOR-induced analgesia in reversing pain hypersensitivities associated with peripheral nerve injury. While systemic administration of KOR agonists attenuates nociceptive sensory transmission, this effect appears to be a stress-induced effect as anxiolytic agents, including delta opioid receptor agonists, mitigate KOR agonist-induced analgesia. Additionally, while the role of KOR and dynorphin in driving the dysphoric and aversive components of stress and drug withdrawal has been well characterized, how this system mediates the negative emotional states associated with chronic pain is relatively unexplored. This review provides evidence that dynorphin and the KOR system contribute to the negative affective component of pain and that this receptor system likely contributes to the high comorbidity of mood disorders associated with chronic neuropathic pain. |
format | Online Article Text |
id | pubmed-4233910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-42339102014-12-01 Does the kappa opioid receptor system contribute to pain aversion? Cahill, Catherine M. Taylor, Anna M. W. Cook, Christopher Ong, Edmund Morón, Jose A. Evans, Christopher J. Front Pharmacol Pharmacology The kappa opioid receptor (KOR) and the endogenous peptide-ligand dynorphin have received significant attention due the involvement in mediating a variety of behavioral and neurophysiological responses, including opposing the rewarding properties of drugs of abuse including opioids. Accumulating evidence indicates this system is involved in regulating states of motivation and emotion. Acute activation of the KOR produces an increase in motivational behavior to escape a threat, however, KOR activation associated with chronic stress leads to the expression of symptoms indicative of mood disorders. It is well accepted that KOR can produce analgesia and is engaged in chronic pain states including neuropathic pain. Spinal studies have revealed KOR-induced analgesia in reversing pain hypersensitivities associated with peripheral nerve injury. While systemic administration of KOR agonists attenuates nociceptive sensory transmission, this effect appears to be a stress-induced effect as anxiolytic agents, including delta opioid receptor agonists, mitigate KOR agonist-induced analgesia. Additionally, while the role of KOR and dynorphin in driving the dysphoric and aversive components of stress and drug withdrawal has been well characterized, how this system mediates the negative emotional states associated with chronic pain is relatively unexplored. This review provides evidence that dynorphin and the KOR system contribute to the negative affective component of pain and that this receptor system likely contributes to the high comorbidity of mood disorders associated with chronic neuropathic pain. Frontiers Media S.A. 2014-11-17 /pmc/articles/PMC4233910/ /pubmed/25452729 http://dx.doi.org/10.3389/fphar.2014.00253 Text en Copyright © 2014 Cahill, Taylor, Cook, Ong, Morón and Evans. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cahill, Catherine M. Taylor, Anna M. W. Cook, Christopher Ong, Edmund Morón, Jose A. Evans, Christopher J. Does the kappa opioid receptor system contribute to pain aversion? |
title | Does the kappa opioid receptor system contribute to pain aversion? |
title_full | Does the kappa opioid receptor system contribute to pain aversion? |
title_fullStr | Does the kappa opioid receptor system contribute to pain aversion? |
title_full_unstemmed | Does the kappa opioid receptor system contribute to pain aversion? |
title_short | Does the kappa opioid receptor system contribute to pain aversion? |
title_sort | does the kappa opioid receptor system contribute to pain aversion? |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233910/ https://www.ncbi.nlm.nih.gov/pubmed/25452729 http://dx.doi.org/10.3389/fphar.2014.00253 |
work_keys_str_mv | AT cahillcatherinem doesthekappaopioidreceptorsystemcontributetopainaversion AT taylorannamw doesthekappaopioidreceptorsystemcontributetopainaversion AT cookchristopher doesthekappaopioidreceptorsystemcontributetopainaversion AT ongedmund doesthekappaopioidreceptorsystemcontributetopainaversion AT moronjosea doesthekappaopioidreceptorsystemcontributetopainaversion AT evanschristopherj doesthekappaopioidreceptorsystemcontributetopainaversion |